UBS analyst Andrew Peters reiterated his Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR), which suggests 152 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy; Shares Will ReboundAugust 10, 2015 7:08 AM Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002August 7, 2015 8:30 AM Esperion Therapeutics (ESPR) Tops Q2 EPS by 3cAugust 6, 2015 5:05 PM Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial ResultsAugust 6, 2015 4:05 PM